通冠丸治疗不稳定型心绞痛40例

TongGuan Wan for 40 Cases of Unstable Angina Pectoris

目的:观察通冠丸对不稳定型心绞痛(UA)患者血清超敏C反应蛋白(hs-CRP)、同型半胱氨酸(HCY)的影响。方法:将80例患者随机分为治疗组、对照组各40例。2组均给予西药常规治疗,治疗组在此基础上加用通冠丸,20丸/次,口服,3次/d。治疗4周后观察心绞痛临床疗效及HCY、hs-CRP的水平变化。结果:总有效率治疗组为90.0%,对照组为82.5%,2组无明显差异(P>0.05)。2组治疗后HCY、hs-CRP值均明显下降(P<0.05),治疗组下降更显著(P<0.05)。结论:通冠丸联合西药常规治疗UA临床疗效显著,可显著降低患者血清HCY和hs-CRP水平。

Objective： To observe the influence of TongGuanWan on hypersensitive C-reactive protein （hs-CRP） and homocysteine （HCY） of the patients with unstable angina peetoris （UA）. Method： Altogether 80 patients were divided into the treatment group and the control group randomly, 40 cases each group. Both groups received routine treatment of Western medicine, the treatment group took TongGuanWan orally, 20 pills each time, three times per day. Curative effects, the changes of HCY and hs-CRP were surveyed after treating for four weeks. Result： Total effective rates of the treatment group and the control group were 90.0% and 82.5%, the comparison between both groups showed insignificant difference （P 〉0.05）. HCY and hs-CRP of both groups were decreased remarkably （P〈0.05）the indexes of the treatment group were reduced more notably （P〈0.05）. Conclusion： Tong- GuanWan and routine treatment of Western medicine in treating UA could gain notable effects, which could signifi- cantly lower the levels of HCY and hs-CRP.